Back

Noradrenaline combined with either dobutamine or levosimendan - similar outcome and cardiac biomarker evolution in cardiogenic shock

21 May 2016 (14:21 - 14:27)
Organised by:
Congress Presentation Part of: Rapid Fire 1 - Acute heart failure Acute heart failure (other) HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor Tuukka Tarvasmaki

Helsinki University Hospital, Helsinki (Finland)

14 More presentations in this session

Presentation thumbnail
Twenty five years of acute heart failure in 1800 consecutive patients: no short- and long-term survival improvement.
Mr J. van den Berge (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of multi-organ dysfunction/damage in acute heart failure
Doctor R. Zymlinski (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and prognosis of patients hospitalized for heart failure depending on ejection fraction: analysis of administrative data of a nationwide population
Doctor R. Bover Freire (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Combined measurement of sST2 and NT-proBNP is a very early marker of severity in cardiogenic shock complicating acute coronary syndromes
Doctor H. Tolppanen (Helsinki, FI)
Abstract
Presentation thumbnail
Short and long-term prognostic value of hyponatremia in heart failure with preserved ejection fraction versus reduced ejection fraction: An analysis of the Korean Acute Heart Failure (KorAHF) Registry
Assistant Professor J. Park (Seongnam, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire 1 - Acute heart failure

The Event

Event poster

HEART FAILURE 2016

21 May 2016 14:21 CET
You may be interested in
thumbnail
Congress Presentation
Catecholamines in cardiogenic shock - dosis fecit venenum
21 March 2026
thumbnail
Congress Presentation
Should we use levosimendan?
20 March 2026
thumbnail
Congress Presentation
Inotropic therapy effects on NT-ProBNP values in acute heart failure associated with acute coronary syndrome
21 May 2023
thumbnail
Congress Presentation
Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial
24 March 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources